A5027810181- CNS Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- COVID-19 and Mental Health
- Radiomics and Machine Learning in Medical Imaging
- COVID-19 Clinical Research Studies
- Protein Degradation and Inhibitors
- Vascular Malformations Diagnosis and Treatment
- COVID-19 and healthcare impacts
Memorial Sloan Kettering Cancer Center
2016-2024
Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose this study was describe safety and efficacy PD-1 inhibition patients with refractory HGGs.This Institutional Review Board approved single center retrospective included adult pathologically confirmed HGG who received a inhibitor from 9/2014-10/2016 outside clinical trial at Memorial Sloan Kettering Cancer Center.Twenty five pembrolizumab as part compassionate use program....
Purpose With the rapid spread of COVID-19 in New York City since early March 2020, innovative measures were needed for clinical pharmacy specialists to provide direct care safely cancer patients. Allocating workforce was necessary meet surging needs inpatient services due outbreak, which had potential compromise outpatient services. We present here our approach restructuring and providing patient clinics during pandemic. Data sources conducted a retrospective review electronic documentation...
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive primary brain tumor. While high dose methotrexate (HDMTX) regimens remain standard of care, it remains unclear if optimization HDMTX doses the addition rituximab provide clinical benefit. Over last 30 years, care given at Memorial Sloan Kettering Cancer Center (MSKCC) has evolved, allowing comparison patients receiving different numbers those treated with without rituximab. The purpose this study was to describe...
Aim: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). Patients & methods: We retrospectively reviewed all PCNSL who received rapid infusions (RRI) from January 2016 to 2017. Primary end point was incidence infusion reactions. Results conclusion: 11 a total 44 RRIs. Rituximab dosed at 500 or 750 mg/m2. Premedication included acetaminophen diphenhydramine. No reactions occurred during any RRI. Two were administered...
Abstract BACKGROUND Primary Central Nervous System Lymphoma (PCNSL) is an aggressive rare non-Hodgkin lymphoma. Prognosis particularly poor for relapsed/recurrent (R/R) patients with no established treatment modality. Methotrexate/BCNU/Teniposide/Prednisone or without rituximab has efficacy in newly diagnosed PCNSL. Here, we report and toxicity of RMBVP the R/R METHODS This retrospective study at MSKCC included PCNSLs treated MBVP disease between 5/2009 5/2019. Methotrexate (3.5 g/m2; day 1...
2033 Background: Treatment options for refractory high grade gliomas (HGG) are limited. Programmed cell death ligand-1 (PD-L1) expression has been reported in 0-61% of HGGs and therefore might be a suitable target HGG. The purpose this study was to describe safety efficacy PD-1 inhibition patients with HGGs. Methods: This IRB approved single center retrospective at Memorial Sloan Kettering Cancer Center included pathologically confirmed HGG an age ≥18 years who received inhibitor between...
TPS2074 Background: Leptomeningeal metastases (LM) represent an aggressive form of advanced cancer with few durable therapeutic options. One the principal barriers in treating LM is paucity knowledge on cell survival and proliferation within nutrient-sparse cerebrospinal fluid (CSF). Single-cell RNA sequencing patient-derived CSF has identified that cells spinal employ single iron-binding transporter receptor system, lipocalin-2/SLC22A17, to gather sparse iron sustain their metabolic needs....
Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of combination chemotherapy regimen: methotrexate, carmustine, etoposide, prednisone or without rituximab (RMBVP). This retrospective study included thirty patients who received median two 28-day cycles (0.5–5). The age was 66 years (23–81); KPS 70 (30–90); 14 (46.7%) were women. Patients 2 prior lines therapy all...
To establish the safety and feasibility of rapidly infusing rituximab over 90 minutes in patients with primary CNS lymphoma. Administering at standard rate is meant to minimize infusion reactions though results long times first doses averaging six hours subsequent four hours. In a subset systemic B-cell mediated diseases, safe, feasible, decreases healthcare costs, improves patient satisfaction. We initiated pilot study determine if rapid safe reviewed all lymphoma who received infusions...
An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients recurrent or progressive high grade gliomas (HGG). Data regarding combination and carmustine (BCNU) is limited. The purpose this study compare single agent BCNU versus plus HGGs. This IRB approved center retrospective at Memorial Sloan Kettering Cancer Center included pathologically confirmed HGG an age ≥18 years who received between 6/2014 5/2017. Forty-six HGGs...